GlassScriptPhysician profile
Kenneth Merkatz
NPI 1891794905
$8,131.49
in general payments reported to CMS, 2019-2025
37 companies · $1,727 in 2025
The $1,727 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,643 · 2020: $561 · 2021: $273 · 2022: $926 · 2023: $1,461 · 2024: $1,540 · 2025: $1,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,644 · Education: $83.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,644.11 |
| Education | $83.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $948.12 | 2019-2025 | Gallant, Jot Dx, Cardiomems |
| Janssen Pharmaceuticals, INC | $927.64 | 2019-2024 | Xarelto |
| Amgen INC. | $820.08 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $724.14 | 2022-2025 | Watchman Flx, Watchman, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $683.01 | 2019-2025 | |
| Pfizer INC. | $531.34 | 2019-2025 | |
| Novo Nordisk INC | $463.63 | 2024-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.14 | 2019-2025 | Jardiance |
| Impulse Dynamics (USA) INC. | $324.90 | 2023-2024 | Optimizer, Optimizer |
| Astrazeneca Pharmaceuticals LP | $260.16 | 2019-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $213.77 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $208.45 | 2019 | |
| Bridgebio Pharma, INC. | $188.01 | 2025 | Attruby |
| Bracco Diagnostics INC. | $143.60 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.61 | 2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $120.69 | 2022-2024 | Verquvo |
| Biotronik INC. | $112.24 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $102.27 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $99.83 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $96.04 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $94.52 | 2019-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $87.79 | 2022-2023 | Arcalyst |
| Medtronic, INC. | $83.19 | 2025 | Symplicity G3 |
| Daiichi Sankyo INC. | $63.01 | 2023-2024 | Injectafer |
| Heartflow, INC. | $62.39 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $60.65 | 2024 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $48.05 | 2019-2022 | |
| Atricure, INC. | $29.52 | 2025 | Atriclip Laa Exclusion System |
| Baxter Healthcare | $29.38 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Azurity Pharmaceuticals, INC. | $24.20 | 2023 | Edarbi |
| Lundbeck LLC | $21.47 | 2019 | |
| Amarin Pharma, INC. | $20.78 | 2019 | |
| Tactile Systems Technology INC | $15.78 | 2024 | Flexitouch Plus, Entre Plus |
| Abiomed | $15.75 | 2024 | Impella |
| Kowa Pharmaceuticals America, INC. | $15.68 | 2019 | |
| Esperion Therapeutics, INC. | $15.03 | 2025 | Nexletol |
| Strongbridge US INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Merkatz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.